1. Home
  2. BBVA vs VRTX Comparison

BBVA vs VRTX Comparison

Compare BBVA & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BBVA

Banco Bilbao Vizcaya Argentaria S.A.

HOLD

Current Price

$25.66

Market Cap

134.0B

Sector

Finance

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$474.70

Market Cap

124.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBVA
VRTX
Founded
1857
1989
Country
Spain
United States
Employees
126877
N/A
Industry
Commercial Banks
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
134.0B
124.7B
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
BBVA
VRTX
Price
$25.66
$474.70
Analyst Decision
Buy
Buy
Analyst Count
2
29
Target Price
N/A
$539.69
AVG Volume (30 Days)
1.4M
1.6M
Earning Date
04-30-2026
05-04-2026
Dividend Yield
4.08%
N/A
EPS Growth
N/A
836.54
EPS
N/A
4.02
Revenue
N/A
$2,488,652,000.00
Revenue This Year
$29.69
$10.79
Revenue Next Year
$5.39
$10.47
P/E Ratio
$11.24
$119.63
Revenue Growth
N/A
46.20
52 Week Low
$14.63
$362.50
52 Week High
$26.40
$533.67

Technical Indicators

Market Signals
Indicator
BBVA
VRTX
Relative Strength Index (RSI) 62.12 47.96
Support Level $23.10 $422.12
Resistance Level $26.25 $486.26
Average True Range (ATR) 0.37 16.00
MACD -0.01 -3.73
Stochastic Oscillator 69.63 7.10

Price Performance

Historical Comparison
BBVA
VRTX

About BBVA Banco Bilbao Vizcaya Argentaria S.A.

Despite its Spanish origins, Banco Bilbao Vizcaya Argentaria generates only around one-fourth of its profits in Spain. We expect that on a normalized basis, BBVA's market-leading Mexican bank should contribute half of its earnings, while its Turkish operation should account for another 15%. The balance of BBVA's earnings comes from smaller operations in South America. BBVA is overwhelmingly a retail and commercial bank, with corporate and investment banking forming a minor part of the overall business. BBVA also offers insurance and investment products through its banking networks.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: